Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This study is to confirm the potential effects and assess the safety of a new bio-product
Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA) and
Ribavirin（RBV） in the treatment of Chronic hepatitis C who have not been previously treated
with Interferon.